Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Carbamazepine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 0.57 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.57 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | P2RX4 | Q99571 | 16/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamazepine SCHEMBL6477112 | 0.76 | LMNA (1.00) | TSHRLMNAMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL31685158 | 0.76 | LMNA (1.00) | TSHRLMNAMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL21639 | 0.76 | LMNA (1.00) | TSHRLMNAMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL29433237 | 0.76 | LMNA (1.00) | TSHRLMNAMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL29360181 | 0.76 | LMNA (1.00) | TSHRLMNAMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL5382102 | 0.74 | LMNA (0.96) | TSHRLMNAMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL29023618 | 0.74 | LMNA (0.96) | TSHRLMNAMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL1421962 | 0.74 | LMNA (0.96) | TSHRLMNAMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL29390487 | 0.74 | LMNA (0.96) | TSHRLMNAMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL28169915 | 0.74 | LMNA (0.96) | TSHRLMNAMAPK1SCN4ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200276166-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | UNIV CALIFORNIA (US) | 2020-09-03 | — | — | US | disclosed |
| US-10668049-B2 | Methods of treating cognitive decline with transforming growth factor beta inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-06-02 | — | — | US | disclosed |
| US-20160367530-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-12-22 | — | — | US | disclosed |
| US-9468649-B2 | Methods of treating epilepsy with transforming growth factor beta inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-10-18 | — | — | US | disclosed |
| US-20120058949-A1 | Methods of Treating Neurological Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2012-03-08 | — | — | US | disclosed |
| WO-2010065917-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-06-10 | — | — | WO | disclosed |